{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:36:22Z","timestamp":1791520582762,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M711410"],"award-info":[{"award-number":["2022M711410"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["22KJB320014"],"award-info":[{"award-number":["22KJB320014"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["22KJB320014"],"award-info":[{"award-number":["22KJB320014"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced prostate cancer (PCa) is associated with a poor prognosis, particularly in patients who progress to castration-resistant prostate cancer (CRPC). The emergence of enzalutamide (Enz), a second-generation androgen receptor inhibitor, has effectively extended the median survival of these patients. However, drug resistance frequently develops during clinical use. Multiple studies have suggested that ferroptosis inducers can reverse cancer resistance to Enz, though the exact mechanisms remain unclear. In this study, we found that CRPC cells exhibit a concentration-dependent decrease in ferroptosis in response to Enz. This change is attributed to the upregulation of the protein level of SLC7A11. Protein stability assays and database analyses showed that SLC7A11 undergoes post-translational modification, likely connected to Enz-mediated downregulation of the SLC7A11-specific E3 ubiquitin ligase NEDD4L. This phenomenon was significantly reversed by the addition of erastin, a targeted inhibitor of the cystine\/glutamate transport system Xc-. The data from both in vitro and in vivo experiments indicate that combining Enz with erastin significantly inhibits the proliferation of drug-resistant CRPC cells, thereby enhancing tumor suppression. These findings offer novel insights into targeting SLC7A11 with erastin as a potential strategy to overcome Enz resistance.<\/jats:p>","DOI":"10.1038\/s41419-025-07809-4","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:20:49Z","timestamp":1754392849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Min","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luotong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengtao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chesong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-6445","authenticated-orcid":false,"given":"Bianjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9621-9590","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"7809_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020;31:470\u20139.","journal-title":"Ann Oncol"},{"key":"7809_CR2","doi-asserted-by":"crossref","unstructured":"Est\u00e9banez-Perpi\u00f1\u00e1 E, Bevan CL, McEwan IJ. Eighty years of targeting androgen receptor activity in prostate cancer: the fight goes on. Cancers. 2021;13:509.","DOI":"10.3390\/cancers13030509"},{"key":"7809_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/1097-0142(19930201)71:3+<1059::AID-CNCR2820711426>3.0.CO;2-6","volume":"71","author":"F Labrie","year":"1993","unstructured":"Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer. 1993;71:1059\u201367.","journal-title":"Cancer"},{"key":"7809_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd4068","volume":"12","author":"D Trewartha","year":"2013","unstructured":"Trewartha D, Carter K. Advances in prostate cancer treatment. Nature Rev Drug Discov. 2013;12:823\u20134.","journal-title":"Nature Rev Drug Discov"},{"key":"7809_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178:239\u201361.","journal-title":"Br J Pharmacol"},{"key":"7809_CR6","doi-asserted-by":"publisher","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","volume":"7","author":"MT Schweizer","year":"2015","unstructured":"Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.","journal-title":"Sci Transl Med"},{"key":"7809_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/pros.23209","volume":"76","author":"MT Schweizer","year":"2016","unstructured":"Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, et al. Bipolar androgen therapy for men with androgen ablation na\u00efve prostate cancer: results from the phase II BATMAN study. Prostate. 2016;76:1218\u201326.","journal-title":"Prostate"},{"key":"7809_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"7809_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.001","volume":"81","author":"O Snow","year":"2019","unstructured":"Snow O, Lallous N, Singh K, Lack N, Rennie P, Cherkasov A. Androgen receptor plasticity and its implications for prostate cancer therapy. Cancer Treat Rev. 2019;81:101871.","journal-title":"Cancer Treat Rev"},{"key":"7809_CR10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/onc.2013.235","volume":"33","author":"X Yuan","year":"2014","unstructured":"Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014;33:2815\u201325.","journal-title":"Oncogene"},{"key":"7809_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol cell Biol"},{"key":"7809_CR12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41418-020-00685-9","volume":"28","author":"WD Bao","year":"2021","unstructured":"Bao WD, Pang P, Zhou XT, Hu F, Xiong W, Chen K, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer\u2019s disease. Cell Death Differ. 2021;28:1548\u201362.","journal-title":"Cell Death Differ"},{"key":"7809_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385.","journal-title":"Cell"},{"key":"7809_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2:e1054549.","journal-title":"Mol Cell Oncol"},{"key":"7809_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nature Rev Clin Oncol. 2021;18:280\u201396.","journal-title":"Nature Rev Clin Oncol"},{"key":"7809_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180\u201391.","journal-title":"Nat Cell Biol"},{"key":"7809_CR17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673\u201385.","journal-title":"Cancer Discov"},{"key":"7809_CR18","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429\u201341.","journal-title":"Onco Targets Ther"},{"key":"7809_CR19","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.celrep.2019.10.068","volume":"29","author":"JH Hwang","year":"2019","unstructured":"Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, et al. CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer. Cell Rep. 2019;29:2355\u201370.e6.","journal-title":"Cell Rep"},{"key":"7809_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","volume":"571","author":"EJ Adams","year":"2019","unstructured":"Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571:408\u201312.","journal-title":"Nature"},{"key":"7809_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30257-z","volume":"13","author":"X Qiu","year":"2022","unstructured":"Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022;13:2559.","journal-title":"Nat Commun"},{"key":"7809_CR22","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41388-022-02272-3","volume":"41","author":"C Wang","year":"2022","unstructured":"Wang C, Leavenworth J, Zhang C, Liu Z, Yuan KY, Wang Y, et al. Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer. Oncogene. 2022;41:2778\u201385.","journal-title":"Oncogene"},{"key":"7809_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-13-0405","volume":"3","author":"WG Nelson","year":"2013","unstructured":"Nelson WG, Yegnasubramanian S. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov. 2013;3:971\u20134.","journal-title":"Cancer Discov"},{"key":"7809_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","volume":"5","author":"M Isikbay","year":"2014","unstructured":"Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72\u201389.","journal-title":"Horm Cancer"},{"key":"7809_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","volume":"14","author":"V Murillo-Garz\u00f3n","year":"2017","unstructured":"Murillo-Garz\u00f3n V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14:683\u201396.","journal-title":"Nat Rev Urol"},{"key":"7809_CR26","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1158\/1078-0432.CCR-21-1846","volume":"28","author":"E Dylgjeri","year":"2022","unstructured":"Dylgjeri E, Kothari V, Shafi AA, Semenova G, Gallagher PT, Guan YF, et al. A novel role for DNA-PK in metabolism by regulating glycolysis in castration-resistant prostate cancer. Clin Cancer Res. 2022;28:1446\u201359.","journal-title":"Clin Cancer Res"},{"key":"7809_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/2159-8290.CD-20-0789","volume":"11","author":"E Koren","year":"2021","unstructured":"Koren E, Fuchs Y. Modes of regulated cell death in cancer. Cancer Discov. 2021;11:245\u201365.","journal-title":"Cancer Discov"},{"key":"7809_CR28","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1111\/cas.14181","volume":"110","author":"M Yu","year":"2019","unstructured":"Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019;110:3173\u201382.","journal-title":"Cancer Sci"},{"key":"7809_CR29","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3389\/fonc.2019.01398","volume":"9","author":"HH Zhou","year":"2019","unstructured":"Zhou HH, Chen X, Cai LY, Nan XW, Chen JH, Chen XX, et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front Oncol. 2019;9:1398.","journal-title":"Front Oncol"},{"key":"7809_CR30","first-page":"826","volume":"42","author":"H Yu","year":"2019","unstructured":"Yu H, Yang C, Jian L, Guo S, Chen R, Li K, et al. Sulfasalazine\u2011induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol Rep. 2019;42:826\u201338.","journal-title":"Oncol Rep"},{"key":"7809_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","volume":"483","author":"Y Su","year":"2020","unstructured":"Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127\u201336.","journal-title":"Cancer Lett"},{"key":"7809_CR32","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1002\/jcp.29232","volume":"235","author":"X Zhang","year":"2020","unstructured":"Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235:3425\u201337.","journal-title":"J Cell Physiol"},{"key":"7809_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2017.01.004","volume":"104","author":"S Galadari","year":"2017","unstructured":"Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med. 2017;104:144\u201364.","journal-title":"Free Radic Biol Med"},{"key":"7809_CR34","doi-asserted-by":"crossref","unstructured":"Lee J, Roh JL. SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer. Antioxidants. 2022;11:2444.","DOI":"10.3390\/antiox11122444"},{"key":"7809_CR35","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81:1583\u201394.","journal-title":"Cancer Res"},{"key":"7809_CR36","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.3739","volume":"20","author":"D Popovic","year":"2014","unstructured":"Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20:1242\u201353.","journal-title":"Nat Med"},{"key":"7809_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41418-022-00951-y","volume":"29","author":"Y Fan","year":"2022","unstructured":"Fan Y, Hou T, Dan W, Zhu Y, Liu B, Wei Y, et al. ERK1\/2 inhibits Cullin 3\/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression. Cell Death Differ. 2022;29:1611\u201324.","journal-title":"Cell Death Differ"},{"key":"7809_CR38","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1038\/s41388-022-02316-8","volume":"41","author":"P Gao","year":"2022","unstructured":"Gao P, Hao JL, Xie QW, Han GQ, Xu BB, Hu H, et al. PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer. Oncogene. 2022;41:2945\u201357.","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1038\/s41419-025-08123-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07809-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:29Z","timestamp":1763534129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07809-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7809"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07809-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-025-08123-9","URL":"https:\/\/doi.org\/10.1038\/s41419-025-08123-9","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals and were approved by the Medical Center Animal Care and Use Committee of Nanjing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants involved in this study have provided informed consent for their data to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"591"}}